Shanghai Pharmaceuticals Holding (601607) Stock Price, News, Quotes-Moomoo

CN Stock MarketDetailed Quotes

601607 Shanghai Pharmaceuticals Holding

Watchlist

21.37
0.000.00%

Not Open Dec 4 15:00 CST

79.23BMarket Cap19.68P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

sh pharma (601607.SH): The application for the market approval of butanedioic acid linagliptin ester capsules has been approved.
On December 4, Gelonghui reported that sh pharma (601607.SH) announced that in October 2021, its wholly-owned subsidiary Shanghai Shennong Xinyi Pharmaceutical Factory Co., Ltd. signed a "Cooperation Agreement" with Guizhou Shengnuo Biotechnology Co., Ltd. and its wholly-owned subsidiary, obtaining exclusive commission manufacturing and industrial sales rights for the active pharmaceutical ingredient and formulation of the X842 project (i.e., "pentanedioic acid linaclotide ester capsules") in the region of china. Recently, the X842 project developed in cooperation with Guizhou Shengnuo has received the "Drug Registration Certificate" issued by the National Medical Products Administration, and the drug market approval application has been approved by the National Medical Products Administration.
Gelonghui FinanceDec 4 02:38 ET
Shanghai Pharma Gets Nod to Produce Apremilast Tablets
MT NewswiresDec 4 00:44 ET
Market bullish stimulus boosts Hong Kong pharmaceutical stocks, with Genshuo Niaoyao rising over 14%.
① What bullish impacts does the medical insurance centralized procurement have on pharmaceutical companies? ② How do institutions view the subsequent development of pharmaceutical stocks?
cls.cnDec 2 21:48 ET
Shanghai Pharmaceuticals Holding Co., Ltd (SHSE:601607) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Simply Wall StDec 2 20:53 ET
Shanghai Pharmaceuticals' Trial on Drug for Stroke Patients Shows Positive Results
MT NewswiresDec 2 00:44 ET
China Securities Co.,Ltd.: In the 2024 version of the medical insurance catalog, the number of innovative drugs added has reached a new high, balancing 'ensuring basic coverage' and 'supporting genuine innovation'.
Overall situation of the 2024 medical insurance catalog: the results are stable, meeting expectations, with a record high in the number of new innovative drugs, reflecting a balanced consideration of fund safety, public medical needs, and support for innovation.
Zhitong FinanceDec 2 00:42 ET

Comments

Moomoo AI

Feb 20 22:29

The company's consistent ROCE and capital increase hint at a lack of high return investments. High current liabilities to total assets ratio may pose risks. The stock's low return to shareholders over the past five years shows lackluster trends.

Return Trends At Shanghai Pharmaceuticals Holding (SHSE:601607) Aren't Appealing

Moomoo AI

Dec 17, 2023 18:39

Shanghai Pharmaceuticals Holding's declining earnings and anticipated lower growth may signal a less prosperous future. This, combined with a lack of earnings growth improvement, could prevent a significant share price increase in the near term.

Shanghai Pharmaceuticals Holding Co., Ltd's (SHSE:601607) Prospects Need A Boost To Lift Shares

Moomoo AI

Nov 29, 2023 19:44

The market may have anticipated the fall in EPS, or it might expect the situation to get better. Dividend payments largely explain the divergence between the TSR and share price return over five years. Significant improvement in fundamental performance is needed to reverse the downward trend in the stock value.

Shanghai Pharmaceuticals Holding (SHSE:601607) Investors Are Sitting on a Loss of 2.5% If They Invested Five Years Ago

Moomoo AI

Nov 11, 2023 18:43

The company's poor and stagnant return on capital invested, the surge in capital used, and the significant short-term debt obligations suggest a lackluster performance. It doesn't exhibit the traits of a prospective multi-bagger stock.